RALEIGH, N.C.--(BUSINESS WIRE)--June 14, 2006--Respirics Inc. announces the commercial launch of MD Turbo, a companion product designed to solve two of the biggest problems patients with Asthma & COPD have with their pressurized metered dose inhalers (pMDI). MD Turbo will be marketed in the United States by TEAMM Pharmaceuticals, Inc., a subsidiary of Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI - News).
